Future pain treatment;Fremtidig smertebehandling

Tidsskrift for den Norske Laegeforening

Volumn 121, Issue 16, 2001, Pages 1917-1922

  Rygh, Lars Jorgen ^a,b   Fagerlund, Tore Hind ^c,d   Svendsen, Frode ^e  

^a Fysiologisk Institutt   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c Ullevål Sykehus ^*  (Norway)

^d Smerte Medisinsk Institutt   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OPIATE RECEPTOR;

ANALGESIA; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; GENE THERAPY; GENETICS; HUMAN; METHODOLOGY; NERVE CELL PLASTICITY; NOCICEPTIVE RECEPTOR; PAIN; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PHARMACOGENETICS; PHYSIOLOGY; RESEARCH; REVIEW; SPINAL CORD; SYNAPTIC TRANSMISSION;

ANALGESIA; ANALGESICS; ANIMALS; GENE THERAPY; HUMANS; MODELS, NEUROLOGICAL; NEURONAL PLASTICITY; NOCICEPTORS; PAIN; PERIPHERAL NERVOUS SYSTEM; PHARMACOGENETICS; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, OPIOID; RESEARCH; SPINAL CORD; SYNAPTIC TRANSMISSION;

EID: 0035919426     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Mannion RJ, Woolf CJ. Pain mechanisms and management: a central perspective. Clin J Pain 2000; 16 (suppl 3): 144-56.
2. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol 1997; 14: 2-31.
3. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1999; 57: 1-164.
4. Costigan M, Woolf CJ. Pain: molecular mechanisms. The Journal of Pain 2000; 1 (suppl 1): 35-44.
5. Dickenson AH, Chapman V, Green GM. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. Gen Pharmacol 1997; 28: 633-8.
6. Akopian AN, Souslova V, England S, Okuse K, Ogata N, Ure J et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 1999; 2: 541-8.
7. Okuse K, Chaplan SR, McMahon SB, Luo ZD, Calcutt NA, Scott BP et al. Regulation of expression of the sensory neuron-specific sodium channel SNS in inflammatory and neuropathic pain. Mol Cell Neurosci 1997; 10: 196-207.
8. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000; 405: 183-7.
9. Rygh LJ, Kontinen VK, Suzuki R, Dickenson AH. Different increase in C-fibre evoked responses after nociceptive conditioning stimulation in sham-operated and neuropathic rats. Neurosci Lett 2000; 288: 99-102.
10. Chapman V, Suzuki R, Chamarette HL, Rygh LJ, Dickenson AH. Effects of systemic carbamazepine and gabapentin on spinal neuronal re-sponses in spinal nerve ligated rats. Pain 1998; 75: 261-72.
11. Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology 1987; 26: 1235-8.
12. Dickenson AH, Sullivan AF. Differential effects of excitatory amino acid antagonists on dorsal horn nociceptive neurones in the rat. Brain Res 1990; 506: 31-9.
13. Svendsen F, Rygh LJ, Hole K, Tjølsen A. Dorsal horn NMDA receptor function is changed after peripheral inflammation. Pain 1999; 83: 517-23.
14. Svendsen F, Tjølsen A, Rygh LJ, Hole K. Expression of long-term potentiation in single wide dynamic range neurons in the rat is sensitive to blockade of glutamate receptors. Neurosci Lett 1999; 259: 25-8.
15. Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991; 44: 293-9.
16. Stubhaug A, Breivik H, Eide PK, Kreunen M, Foss A. Mapping of punctuate hyperalgesia around a surgical incision demonstrates that ketamine is a powerful suppressor of central sensitization to pain following surgery. Acta Anaesthesiol Scand 1997; 41: 1124-32.
17. Eide PK, Stubhaug A. Relief of glossopharyngeal neuralgia by ketamine-induced N-methyl-aspartate receptor blockade. Neurosurgery 1997; 41: 505-8.
18. Eide PK, Stubhaug A, Stenehjem AE. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Neurosurgery 1995; 37: 1080-7.
19. Eide PK, Jorum E, Stubhaug A, Bremnes J, Breivik H. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain 1994; 58: 347-54.
20. Malmberg AB, Chen C, Tonegawa S, Basbaum AI. Preserved acute pain and reduced neuropathic pain in mice lacking PKCgamma. Science 1997; 278: 279-83.
21. Wallace MS. Calcium and sodium channel antagonists for the treatment of pain. Clin J Pain 2000; 16 (suppl 2): 80-5.
22. Nicholson B. Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand 2000; 101: 359-71.
23. Atanassoff PG, Hartmannsgruber MW, Thrasher J, Wermeling D, Longton W, Gaeta R et al. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute post-operative pain. Reg Anesth Pain Med 2000; 25: 274-8.
24. Stanfa LC, Sullivan AF, Dickenson AH. Alterations in neuronal excitability and the potency of spinal mu, delta and kappa opioids after carrageenan-induced inflammation. Pain 1992; 50: 345-54.
25. Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken P et al. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 1998; 279: 77-81.
26. Decker MW, Meyer MD. Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics. Biochem Pharmacol 1999; 58: 917-23.
27. Online Mendelian Inheritance of Man, Entry 256800. www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM (3.1.2001).
28. Online Mendelian Inheritance of Man, Entry191315. www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM (3.1.2001).
29. Online Mendelian Inheritance of Man, Entry 162030. www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM (3.1.2001).
30. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87: 543-52.
31. Peroutka SJ. Genetic basis of migraine. Clin Neurosci 1998; 5: 34-7.
32. Nyholt DR, Dawkins JL, Brimage PJ, Goadsby PJ, Nicholson GA, Griffiths LR. Evidence for an X-linked genetic component in familial typical migraine. Hum Mol Genet 1998; 7: 459-63.
33. Martin N, Boomsma D, Machin G. A twin-pronged attack on complex traits. Nat Genet 1997; 17: 387-92.
34. Ziegler DK, Hur YM, Bouchard TJ jr., Hassanein RS, Barter R. Migraine in twins raised together and apart. Headache 1998; 38: 417-22.
35. Honkasalo ML, Kaprio J, Winter T, Heikkila K, Sillanpaa M, Koskenvuo M. Migraine and concomitant symptoms among 8167 adult twin pairs. Headache 1995; 35: 70-8.
36. Larsson B, Bille B, Pedersen NL. Genetic influence in headaches: a Swedish twin study. Headache 1995; 35: 513-9.
37. Treloar SA, Martin NG, Heath AC. Longitudinal genetic analysis of menstrual flow, pain, and limitation in a sample of Australian twins. Behav Genet 1998; 28: 107-16.
38. Bengtsson B, Thorson J. Back pain: a study of twins. Acta Genet Med Gemellol 1991; 40: 83-90.
39. Heikkila JK, Koskenvuo M, Heliovaara M, Kurppa K, Riihimaki H, Heikkila K et al. Genetic and environmental factors in sciatica. Evidence from a nationwide panel of 9365 adult twin pairs. Ann Med 1989; 21: 393-8.
40. Panocka I, Marek P, Sadowski B. Differentiation of neurochemical basis of stress-induced analgesia in mice by selective breeding. Brain Res 1986; 397: 156-60.
41. Elmer GI, Pieper JO, Negus SS, Woods JH. Genetic variance in nociception and its relationship to the potency of morphine-induced analgesia in thermal and chemical tests. Pain 1998; 75: 129-40.
42. Mogil JS, Kest B, Sadowski B, Belknap JK. Differential genetic mediation of sensitivity to morphine in genetic models of opiate antinociception: influence of nociceptive assay. J Pharmacol Exp Ther 1996; 276: 532-44.
43. Berkley KJ. Sex differences in pain. Behav Brain Sci 1997; 20: 371-80.
44. Uhl GR, Sora I, Wang Z. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A 1999; 96: 7752-5.
45. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998; 95: 9608-13.
46. Mayer P, Rochlitz H, Rauch E, Rommelspacher H, Hasse HE, Schmidt S et al. Association between a delta opioid receptor gene polymorphism and heroin dependence in man. Neuroreport 1997; 8: 2547-50.
47. Finegold AA, Mannes AJ, Iadarola MJ. A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain. Hum Gene Ther 1999; 10: 1251-7.
48. Wilson SP, Yeomans DC, Bender MA, Lu Y, Goins WF, Glorioso JC. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci U S A 1999; 96: 3211-6.
49. Abruzzese RV, Godin D, Mehta V, Perrard JL, French M, Nelson W et al. Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmidbased autoinducible GeneSwitch system. Mol Ther 2000; 2: 276-87.
50. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997; 8: 161-70.